novo nordisk cagrisema

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

AOL · 1d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The New York Times · 11h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Wegovy sales double to boost Novo Nordisk's 4th quarter

Reuters · 13h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

The Wall Street Journal on MSN · 19h

Novo Nordisk Expects Slowing Sales Growth This Year

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs.

Investopedia on MSN · 16h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

8hon MSN

Novo doubles down on next-gen weight loss therapy despite early setback

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

4hon MSN

Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

New York, New York-- (Newsfile Corp. - February 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

Novo Nordisk Shares Have a Long Road Back from 40% Slump

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk's next-gen obesity drug Cagrisema

Wegovy sales double to boost Novo Nordisk's 4th quarter

Related topics